Book contents
- Practical Psychopharmacology
- Practical Psychopharmacology
- Copyright page
- Dedication
- Contents
- Foreword
- Preface
- Abbreviations
- Part I General Principles
- 1 Core Concepts of Good Psychopharmacology
- 2 Targets of Treatment: Categories versus Dimensions of Psychopathology
- 3 Interpreting and Using the Literature: Integrating Evidence-Based Trials with Real-World Practice
- 4 Placebo and Nocebo Effects
- 5 Tailoring the Fit: Moderators and Mediators of Treatment Outcome
- 6 Complex Regimens and Rationale-Based Combination Drug Therapies
- 7 Laboratory Values and Psychiatric Symptoms: What to Measure, What Not to Measure, and What to Do With The Results
- 8 Pharmacogenetics: When Relevant, When Not
- 9 Cross-tapering and the Logistics of Drug Discontinuation
- 10 Managing Major Adverse Drug Effects: When to Avoid, Switch, or Treat Through
- 11 Novel Drug Therapeutics: Nutraceuticals, Steroids, Probiotics, and Other Dietary Supplements
- 12 Human Diversity and Considerations in Special Populations
- Part II Targets of Pharmacotherapy
- References
- Index
7 - Laboratory Values and Psychiatric Symptoms: What to Measure, What Not to Measure, and What to Do With The Results
from Part I - General Principles
Published online by Cambridge University Press: 19 October 2021
- Practical Psychopharmacology
- Practical Psychopharmacology
- Copyright page
- Dedication
- Contents
- Foreword
- Preface
- Abbreviations
- Part I General Principles
- 1 Core Concepts of Good Psychopharmacology
- 2 Targets of Treatment: Categories versus Dimensions of Psychopathology
- 3 Interpreting and Using the Literature: Integrating Evidence-Based Trials with Real-World Practice
- 4 Placebo and Nocebo Effects
- 5 Tailoring the Fit: Moderators and Mediators of Treatment Outcome
- 6 Complex Regimens and Rationale-Based Combination Drug Therapies
- 7 Laboratory Values and Psychiatric Symptoms: What to Measure, What Not to Measure, and What to Do With The Results
- 8 Pharmacogenetics: When Relevant, When Not
- 9 Cross-tapering and the Logistics of Drug Discontinuation
- 10 Managing Major Adverse Drug Effects: When to Avoid, Switch, or Treat Through
- 11 Novel Drug Therapeutics: Nutraceuticals, Steroids, Probiotics, and Other Dietary Supplements
- 12 Human Diversity and Considerations in Special Populations
- Part II Targets of Pharmacotherapy
- References
- Index
Summary
Psychiatrists probably are not so unusual among health care professionals in their desire to measure things. But compared to practitioners in most other areas of medicine, they may be the newest entrants to the world of the quantitative versus qualitative. Measurement-based care (MBC) and laboratory testing have become increasing focal points of clinical practice. Perhaps this comes in response to decades (if not centuries) of an often impressionistic and sometimes sluggishly qualitative way of recording clinical observations; perhaps it is backlash against a psychoanalytic heritage that for too long eschewed quantitative measures and formal outcome tracking; it also reflects the promulgation of research tools (semi-structured interviews, questionnaires, rating scales) into nonresearch clinical settings; and no doubt, MBC has arisen in response to a health care system that has come to link service reimbursement with quantifiable parameters.
- Type
- Chapter
- Information
- Practical PsychopharmacologyTranslating Findings From Evidence-Based Trials into Real-World Clinical Practice, pp. 129 - 148Publisher: Cambridge University PressPrint publication year: 2021